Skip to Main Content

The Johns — Milligan and Martin — are leaving Gilead Sciences, marking a significant and uncertain transition in the executive offices of the large-cap biotech.

Milligan said Wednesday that he will step down as Gilead’s CEO and leave the company’s board at the end of the year. A replacement has not been named but Gilead’s board is starting a search.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!